The present invention features systems and methods for preventing amyloid plaque development by treating plaque precursors to arrest or reverse binding of the plaque forming elements. Proteins, protein binding precursors, fragments, other bioactives or biosimilars are inserted to arrest plaque precipitation and aggregation. Hereditary cystatin C Amyloid Angiopathy (HCCAA) is a disease characterized by early and prolific plaque formation whose effective management is analogous to that of other more common amyloidosis. The cystatin C protein that serves as the key to HCCAA plaques colocalizes, coprecipitates and coglommerates with proteins found in other plaques such as those in Alzheimer's disease. The systems, including chemical and biochemical interventions, useful for treating HCCAA are applicable to slowing, preventing and even reversing these amyloids.

The present invention relates generally to a method of detecting a risk of the progression of a pre-invasive neoplasia of the glandular epithelium. More particularly, the present invention provides a method of detecting a risk of the progression from a pre-invasive breast neoplasia by screening for the level of expression of Stefin A in the myoepithelial cells. The method of the present invention is useful in a range of applications including, but not limited to, assessing a neoplastic condition, monitoring the progression of such a condition, predicting the likelihood of a subject progressing to a more advance disease state or informing decisions in relation to the design of treatment schedules.

Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatiodi arthritis. Crohn's disease, and ulcerative colitis.

Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.

Provided is a method for further improving therapeutic effect and cost efficiency by ascertaining cancer type and treatment responsiveness for individual patients. The invention provides a method which includes providing information regarding cancer type of a subject, comprising assessing the cancer type of the subject using a marker relating to the amount of a D-amino acid in blood of the subject, and providing information relating to the cancer type of the subject, based on the assessment results, as well as a system for providing information pertaining to cancer in a subject, which carries out the method.

Methods of determining the risk of an adverse cardiovascular event or death in a mammal are provided which include determining in a biological sample obtained from the mammal the level of a combination of biomarkers selected from a glucose metabolism biomarker, a heart function biomarker, a renal function biomarker and at least one biomarker of cardiac injury. A score is allotted based on the level of each biomarker, and the cumulative score is indicative of the risk of an adverse cardiovascular event.

The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.

The present invention is based on the discovery that three proteins, Cystatin B, Chaperonin 10, and Profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin by monitoring the presence of these markers in biological samples. The invention is also directed to markers for therapeutic efficacy.

Provided is a measurement method with which an analyte in a sample containing a high concentration of the analyte can be measured with high accuracy without diluting the sample in multiple stages. An embodiment of the present invention relates to a measurement method for measuring an amount of an analyte in a sample, the method including: a binding step of providing the sample to a containing part of a measuring chip including the containing part for containing liquid, and a first capture body immobilized inside the containing part and having a recognition site that specifically binds to the analyte so as to bind the analyte contained in the sample to the first capture body; and a measurement step of measuring an amount of the analyte bound to the first capture body. The measurement method includes an adjustment step in which a second capture body having a recognition site that specifically binds to the analyte is bound to a part of the analyte in the sample in parallel with the binding step or before the binding step so as to reduce the amount of the analyte capable of binding to the first capture body.

The object of the present invention is to provide a marker substance capable of determining a risk of hyperglycemia in vivo with high accuracy. The present invention provides the following: a marker peptide for determining the risk of hyperglycemia; an antibody or an aptamer bound to the marker peptide for determining the risk of hyperglycemia; a microarray wherein the antibody or the aptamer to be bound to the marker peptide for determining the risk of hyperglycemia has been immobilized onto a carrier; a method of determining the risk of hyperglycemia wherein an amount or the presence/absence of the marker peptide for determining the risk of hyperglycemia is measured in a biological sample collected from a subject; and a kit for determining the risk of hyperglycemia comprising the antibody or the aptamer, or the microarray.